CLOUD technology enables the formulation of peptide, protein, and antibody therapeutics with stable, prolonged durations of action and predictable systemic exposures. CLOUD-based products incorporating aqueous-phase biologics or low molecular weight small molecules are capable of achieving days to weeks of sustained therapeutic activity following subcutaneous injection.
The CLOUD system—highly controllable and customizable—takes advantage of a novel noncovalent complexation process to reduce the solubility, manage the dissolution characteristics, and enhance the stability of the target active pharmaceutical ingredient (API). Once complexed, an API can be formulated in a low-viscosity aqueous or organic vehicle suitable for injection through a fine gauge needle.
CLOUD-based product candidates are in early preclinical development.
- Wright JC, Matriano J. Long acting injections and implants. In: Hillery AM, Park K, eds. Drug Delivery: Fundamentals & Applications. 2nd ed. Boca Raton, FL: CRC Press; 2016:137-170.
- Sekar M, van Osdol W, Yum S, et al. Drug delivery of biologics: a controlled release strategy. Poster session presented at: IBC’s 17th Annual TIDES Conference; 2015 May 3-6.
- Sekar M, van Osdol W, Yum S, et al. Controlled delivery depots of liraglutide, a GLP-1 analogue, via subcutaneous injection. Poster session presented at: IBC’s 17th Annual TIDES Conference; 2015 May 3-6.
- Sekar M, van Osdol W, Yum S, Theeuwes F. Continuous delivery of interferon-α2a via subcutaneous depots. Poster session presented at: American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition; 2012 Oct 14-18.